Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.
de Vos II, Marenghi C, Badenchini F, Boevé ER, Lozano-Uruñuela F, Graefen M, Rannikko AS, Staerman F, Sugimoto M, Kato T, Somford DM, Frydenberg M, Bangma CH, Remmers S, Roobol MJ; Prostate Cancer Research International: Active Surveillance (PRIAS) consortium.
de Vos II, et al.
BJU Int. 2025 Aug;136(2):245-253. doi: 10.1111/bju.16727. Epub 2025 Apr 14.
BJU Int. 2025.
PMID: 40223578
Free PMC article.